On the other hand, a clinical study of ADI-001, a γδ CAR T product, found that in four lymphoma patients who had previously relapsed after autologous anti-CD19 therapy, all achieved CR after ADI-001 [51]. The gene discussed is CD19; the disease is lymphoma.